969TiP Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006

Articles > Article · 2022

Authors: S. Jabbour, B. Lu, X. Fu, Tuncay GÖKSEL, S. Sugawara, A. Song, S. Quinn, P. Yang, M. Reck

Annals of Oncology, International, WoS, 2022, vol 33, pp S990-S990

DOI: 10.1016/j.annonc.2022.07.1095

View details